PCSA Stock Price, Processa Pharmaceuticals, . Quote, Chart

Market Summary

USD1.51-0.16

Market Closed

-9.58%

PCSA Stock Price

View Fullscreen

PCSA RSI Chart

PCSA Valuation

Market Cap

4.3M

Price/Earnings (Trailing)

-0.39

Price/Sales (Trailing)

2.6K

EV/EBITDA

-2.09

Price/Free Cashflow

-0.53

PCSA Price/Sales (Trailing)

PCSA Profitability

EBT Margin

-114077.19%

Return on Equity

-222.91%

Return on Assets

-192.19%

Free Cashflow Yield

-187.04%

PCSA Fundamentals

PCSA Revenue

Revenue (TTM)

22.5K

PCSA Earnings

Earnings (TTM)

-11.1M

Earnings Growth (Yr)

81.52%

Earnings Growth (Qtr)

-15.51%

Breaking Down PCSA Revenue

Last 7 days

-49.3%

Last 30 days

-31.0%

Last 90 days

-71.0%

Trailing 12 Months

-84.9%

How does PCSA drawdown profile look like?

PCSA Financial Health

Current Ratio

7.71

PCSA Investor Care

Buy Backs (1Y)

88.36%

Diluted EPS (TTM)

-41.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	0
2016	80.7K	80.7K	22.5K	0
2015	1.5M	1.4M	1.4M	113.4K
2014	391.7K	762.1K	1.1M	1.5M
2013	149.4K	106.7K	64.0K	21.3K
2012	0	0	0	192.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Processa Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 07, 2024	young david	bought	51,525	2.4536	21,000	pres. research & development
Feb 06, 2024	young david	bought	50,504	2.5252	20,000	pres. research & development
Feb 01, 2024	lin patrick	bought	3,600	2.4	1,500	chief business - strategy off
Jan 31, 2024	lin patrick	bought	5,925	2.37	2,500	chief business - strategy off
Jan 30, 2024	yorke justin w	bought	21,544	2.693	8,000	-
Jan 30, 2024	ng george k	bought	27,000	2.7	10,000	chief executive officer
Jan 01, 2024	young david	acquired	-	-	1,675	pres. research & development
Jan 01, 2024	bigora sian	sold (taxes)	-1,026	2.79	-368	chief development officer
Jan 01, 2024	bigora sian	acquired	-	-	1,675	chief development officer
Jan 01, 2024	young david	sold (taxes)	-1,445	2.79	-518	pres. research & development

Which funds bought or sold PCSA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	reduced	-31.87	-7,660	78,515	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-3,000	-	-%
Feb 15, 2024	Coastal Bridge Advisors, LLC	added	23.73	8,598	21,734	0.01%
Feb 14, 2024	STATE STREET CORP	unchanged	-	3,406	14,316	-%
Feb 14, 2024	Walleye Capital LLC	sold off	-100	-106,916	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-6,612	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	6,249	6,249	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-0.16	3,000	15,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	89.75	63,149	105,536	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	reduced	-20.07	1,902	40,832	-%

Are Funds Buying or Selling PCSA?

Are funds buying PCSA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PCSA

No. of Funds

Unveiling Processa Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Aug 10, 2021	manchester management co llc	0.9%	142,427	SC 13G/A
Jun 11, 2021	yuhan (usa) corp	7.3%	750,000	SC 13G
Apr 08, 2021	manchester management co llc	4.2%	648,300	SC 13G/A
Oct 13, 2020	manchester management co llc	7.4%	1e+06	SC 13G
Oct 13, 2020	young david	14.2%	1,991,168	SC 13D

Recent SEC filings of Processa Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 11, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Feb 21, 2024	8-K	Current Report
Feb 08, 2024	4	Insider Trading

Peers (Alternatives to Processa Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Processa Pharmaceuticals, Inc. News

Latest updates

Processa Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2020Q3	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2
Revenue	100.0%	197	99.00	-	-	5.00	18.00	58.00	-	38.00	1,317	53.00	113	20.00	73.00	126	97.00	19.00	34.00	49.00	97.00
Gross Profit	-	-	-	-	-	5.00	-45.31	16.00	9.00	13.00	-40.77	27.00	43.00	11.00	36.00	45.00	36.00	7.00	-	15.00	43.00
Operating Expenses	1151.2%	2,956	236	829	575	281	176	140	1,891	471	645	689	781	1,295	829	-	-	-	-	-	-
S&GA Expenses	-	423	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-65.2%	533	1,531	574*	6.00	-	5.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	194.1%	186	63.00	63.00	63.00	56.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-Infinity%	-70.46	-	-	-	-	-25*	-25*	-25*	-25*	-25*	-25*	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-3,141	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-Infinity%	-3,071	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-28.4%	5,787	8,083	10,090	12,432	8,620	18,604	21,658	24,301	26,464	29,025	31,138	33,338	25,214	9,589	10,011	10,012	10,883	10,821	11,306	12,078	12,481
Current Assets	-28.8%	5,632	7,907	9,897	12,219	8,387	10,887	13,961	16,384	18,327	20,670	22,566	24,546	16,203	376	577	357	1,007	725	990	1,543	2,020
Cash Equivalents	-31.5%	4,700	6,861	8,700	10,742	6,504	9,055	12,064	14,395	16,498	19,093	20,831	23,048	15,416	325	453	142	692	504	722	1,249	1,741
Net PPE	-5.2%	3.00	3.00	-	-	-	-	-	-	-	-	-	-	484*	3.00	5.00	7.00	9.00	11.00	13.00	15.00	17.00
Liabilities	-12.8%	797	915	931	2,290	1,149	1,364	1,576	1,064	978	1,817	1,896	2,002	2,275	4,062	3,418	2,778	2,871	2,151	2,804	2,954	2,780
Current Liabilities	-11.6%	731	826	821	2,161	999	1,193	1,571	1,058	971	1,226	1,161	1,096	1,221	2,658	1,898	1,246	1,192	292	783	725	646
Shareholder's Equity	-30.4%	4,989	7,168	9,160	10,142	7,471	17,240	20,082	23,237	25,485	27,208	29,242	31,336	22,939	5,527	6,593	7,234	8,013	8,671	8,502	9,124	9,701
Retained Earnings	-3.2%	-75,369	-73,000	-70,900	-68,269	-64,247	-51,235	-45,200	-40,050	-36,823	-33,639	-30,700	-27,495	-25,395	-15,661	-12,589	-11,856	-10,982	-10,207	-9,344	-8,374	-7,624
Additional Paid-In Capital	0.3%	80,658	80,430	80,339	78,709	72,017	68,774	65,595	63,586	62,307	60,846	59,892	58,830	48,334	21,188	19,182	19,090	18,994	18,874	19,246	19,180	19,125
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	29.00	-	-	-	29.00	-	-	22.00	20.00	18.00	16.00	-	12.00
Shares Outstanding	-100.0%	-	24,631	24,531	24,531	16,035	16,200	15,886	15,831	15,710	15,531	15,406	14,584	14,182	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	33,800	-	-	-	95,400	-	-	-	22,000	-	-	-	44,800	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-20.6%	-2,123	-1,760	-2,064	-2,114	-2,492	-2,974	-2,330	-1,802	-2,726	-1,552	-2,193	-2,243	-2,275	29.00	-350	-546	-613	-721	-807	-607	-463
Share Based Compensation	79.7%	257	143	319	342	2,777	3,214	2,009	829	1,120	1,114	865	308	2,373	165	94.00	99.00	116	269	66.00	59.00	24.00
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	42.0%	-30.61	-52.75	-	6,352	-53.60	-35.25	-	-300	131	-185	-23.08	9,876	17,366	-156	661	-2.81	801	504	281	115	-219
Buy Backs	-	-	-	-	-	-	-	-	300	-	-	-	-	-	-	-	-	-	-	-	-	-

PCSA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses
Research and development expenses	$ 5,799,518	$ 11,494,230
General and administrative expenses	5,657,543	8,763,058
Impairment of intangible asset		7,268,143
Operating Loss	(11,457,061)	(27,525,431)
Other Income (Expense)
Interest income, net	335,541	101,202
Net Operating Loss Before Income Tax Benefit	(11,121,520)	(27,424,229)
Income Tax Benefit
Net Loss	$ (11,121,520)	$ (27,424,229)
Net Loss Per Common Share - Basic	$ (8.48)	$ (34.05)
Net Loss Per Common Share - Diluted	$ (8.48)	$ (34.05)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic	1,311,572	805,477
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted	1,311,572	805,477

PCSA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 4,706,197	$ 6,503,595
Prepaid expenses and other	926,300	1,883,134
Total Current Assets	5,632,497	8,386,729
Property and Equipment, net	2,554
Other Assets
Operating lease right-of-use assets, net	146,057	227,587
Other	5,535	5,535
Total Other Assets	151,592	233,122
Total Assets	5,786,643	8,619,851
Current Liabilities
Current maturities of operating lease liability	83,649	78,896
Accounts payable	311,617	327,548
Due to licensor	189,000	189,000
Due to related parties	39	51
Accrued expenses	146,274	403,061
Total Current Liabilities	730,579	998,556
Non-current Liabilities
Non-current operating lease liability	66,905	150,554
Total Liabilities	797,484	1,149,110
Commitments and Contingencies
Stockholders’ Equity
Common stock, par value $0.0001, 100,000,000 shares authorized; 1,291,000 issued and 1,286,000 outstanding at December 31, 2023 and 806,774 issued and 801,774 outstanding at December 31, 2022	129	80
Additional paid-in capital	80,658,111	72,018,222
Treasury stock	(300,000)	(300,000)
Accumulated deficit	(75,369,081)	(64,247,561)
Total Stockholders’ Equity	4,989,159	7,470,741
Total Liabilities and Stockholders’ Equity	$ 5,786,643	$ 8,619,851

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytidine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

CEO	Mr. George K. Ng Esq., J.D.
WEBSITE	processapharmaceuticals.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Processa Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Processa Pharmaceuticals, Inc.? What does PCSA stand for in stocks?

PCSA is the stock ticker symbol of Processa Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Processa Pharmaceuticals, Inc. (PCSA)?

As of Mon Apr 15 2024, market cap of Processa Pharmaceuticals, Inc. is 4.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCSA stock?

You can check PCSA's fair value in chart for subscribers.

What is the fair value of PCSA stock?

You can check PCSA's fair value in chart for subscribers. The fair value of Processa Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Processa Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PCSA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Processa Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether PCSA is over valued or under valued. Whether Processa Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Processa Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCSA.

What is Processa Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, PCSA's PE ratio (Price to Earnings) is -0.39 and Price to Sales (PS) ratio is 2.59 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCSA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Processa Pharmaceuticals, Inc.'s stock?

In the past 10 years, Processa Pharmaceuticals, Inc. has provided -0.521 (multiply by 100 for percentage) rate of return.